News & Updates
Filter by Specialty:

Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.
Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
14 Jun 2024
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024
6-lead ECG device simplifies QT interval monitoring in RR-TB
A handheld, 6-lead electrocardiographic (ECG) device may be an effective triage test that could reduce the need for 12-lead ECG monitoring in resource-limited, rifampin-resistant tuberculosis (RR-TB) treatment settings, according to a diagnostic prospective cohort study.
6-lead ECG device simplifies QT interval monitoring in RR-TB
12 Jun 2024
COVID-19 does mess with the brain even years after infection
A long-term study showed that individuals who have recovered from COVID-19 continued to experience cognitive, psychiatric, and neurological issues, as well as brain functional alteration, even 2 years after being infected.
COVID-19 does mess with the brain even years after infection
06 Jun 2024
FMT eases anxiety, sleep disturbance in postacute COVID-19 syndrome patients
Patients with postacute COVID-19 syndrome (PACS) may benefit from faecal microbiota transplantation (FMT) treatment, which helps reduce anxiety and improve sleep quality, suggests a study.
FMT eases anxiety, sleep disturbance in postacute COVID-19 syndrome patients
05 Jun 2024
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
05 Jun 2024
SABA overused, increases all-cause mortality among HK asthma patients
Overuse of short-acting β2 agonists (SABA) is prevalent among patients with asthma in Hong Kong and associated with an increased risk of all-cause mortality and hospital admissions, according to a local retrospective cohort study, which was part of the global SABINA (SABA Use in Asthma) research programme.